Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 1/2013

01-02-2013 | Review Article

Pathophysiology and treatment of diabetic retinopathy

Authors: Francesco Bandello, Rosangela Lattanzio, Ilaria Zucchiatti, Claudia Del Turco

Published in: Acta Diabetologica | Issue 1/2013

Login to get access

Abstract

In the past years, the management of diabetic retinopathy (DR) relied primarily on a good systemic control of diabetes mellitus, and as soon as the severity of the vascular lesions required further treatment, laser photocoagulation or vitreoretinal surgery was done to the patient. Currently, even if the intensive metabolic control is still mandatory, a variety of different clinical strategies could be offered to the patient. The recent advances in understanding the complex pathophysiology of DR allowed the physician to identify many cell types involved in the pathogenesis of DR and thus to develop new treatment approaches. Vasoactive and proinflammatory molecules, such as vascular endothelial growth factor (VEGF), play a key role in this multifactorial disease. Current properly designed trials, evaluating agents targeting VEGF or other mediators, showed benefits in the management of DR, especially when metabolic control is lacking. Other agents, directing to the processes of vasopermeability and angiogenesis, are under investigations, giving more hope in the future management of this still sight-threatening disease.
Literature
1.
Saddine JB, Honeycutt AA, Narayan KM et al (2008) Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophtahlmol 126:1740–1747CrossRef
2.
Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
3.
UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 352:837–853CrossRef
4.
Fong DS, Aiello LP, Ferris FL, Klein R (2004) Diabetic retinopathy. Diabetes Care 10:2540–2553CrossRef
5.
Bhagat N, Grigorian RA, Tutela A, Zarbin MA (2009) Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 54:1–32PubMedCrossRef
6.
Goh SY, Cooper ME (2008) Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93:1143–1152PubMedCrossRef
7.
Pinach S, Burt D, Berrone E et al (2011) Retinal heat shock protein 25 in early experimental diabetes. Acta Diabetol (epub ahead of print)
8.
Ghanem AA, Elewa A, Arafa LF (2011) Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy. Eur J Ophtahlmol 21:48–54CrossRef
9.
Zong H, Ward M, Stitt AW (2011) AGEs, RAGE, and diabetic retinopathy. Curr DiabRep 11:244–252CrossRef
10.
Chung SS, Chung SK (2005) Aldose reductase in diabetic microvascular complications. Curr Drug Targets 6:475–486PubMedCrossRef
11.
Lorenzi M (2007) The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res 2007:61038PubMedCrossRef
12.
Geraldes P, King GL (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106:1319–1331PubMedCrossRef
13.
Coral K, Angayarkanni N, Gomathy N et al (2009) Homocysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase. Invest Ophthalmol Vis Sci 50:3607–3612PubMedCrossRef
14.
Madsen-Bouterse SA, Kowluru RA (2008) Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 9:315–327PubMedCrossRef
15.
Adamis AP, Berman AJ (2008) Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 30:65–84PubMedCrossRef
16.
Abu El-Asrar AM, Mohammad G, Nawaz MI et al (2012) Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy. Acta Diabetol (epub ahead of print)
17.
Zhang X, Bao S, Hambly BD, Gillies MC (2009) Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol 41:2368–2371PubMedCrossRef
18.
Aiello LP, Bursell S-E, Clermont A et al (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta isoform selective inhibitor. Diabetes 46:1473–1480PubMedCrossRef
19.
Antonetti DA, Barber AJ, Hollinger LA et al (1999) Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. J Biol Chem 274:23463–23467PubMedCrossRef
20.
Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMedCrossRef
21.
Aiello LP, Northrup JM, Keyt BA et al (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1131:1538–1544CrossRef
22.
Funatsu H, Yamashita H, Ikeda T et al (2002) Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 133:537–543PubMedCrossRef
23.
Liu C, Lv XH, Li HX et al (2012) Angiotensin-(1–7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes. Acta Diabetol 49:291–299PubMedCrossRef
24.
Yousefzade G, Nakhaee A (2011) Insulin-induced hypoglycemia and stress oxidative state in healthy people. Acta Diabetol (epub ahead of print)
25.
Gilbert RE, Kelly DJ, Cox AJ et al (2000) Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hypermeability in experimental diabetes. Diabetologia 43:1360–1367PubMedCrossRef
26.
Antonetti D, Klein R, Gardner T (2012) Diabetic retinopathy. Mechanisms of disease. N Engl J Med 366:1227–1239PubMedCrossRef
27.
Bearse M, Han Y, Schneck M et al (2004) Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy. Invest Ophthalmol Vis Sci 45:3259–3265PubMedCrossRef
28.
Han Y, Adams A, Bearse M et al (2004) Multifocal electroretinogram and short-wavelenght automated perimetry measures in diabetic eyes with little or no retinopathy. Arch Ophthalmol 122:1809–1815PubMedCrossRef
29.
Zhang Y, Bhavnani BR (2006) Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. BMC Neurosci 7:49PubMedCrossRef
30.
Davalli AM, Perego C, Folli FB (2012) The potential role of glutamate in the current diabetes epidemic. Acta Diabetol 49:167–183PubMedCrossRef
31.
The PKC-DRS2 Group (2006) Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113:2221–2230CrossRef
32.
VanGuilder HD, Brucklacher AR, Patel K et al (2008) Diabetes downregulates presynaptic proteins and reduced basal synapsin 1 phosphorylation in rat retina. Eur J Neurosci 28:1–11PubMedCrossRef
33.
Seki M, Tanaka T, Nawa H et al (2004) Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53:2412–2419PubMedCrossRef
34.
Wong HC, Boulton M, McLeod D et al (1988) Retinal pigment epithelial cells in culture produce retinal vascular mitogens. Arch Ophthalmol 106:1439–1443PubMedCrossRef
35.
Wang J, Xu X, Elliott MH et al (2010) Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 59:2297–2305PubMedCrossRef
36.
Murakami T, Felinski EA, Antonetti DA (2009) Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem 284:21036–21046PubMedCrossRef
37.
Enge M, Bjarnegård M, Gerhardt H et al (2002) Endothelium-specific platelet-derived growth factor-β ablation mimics diabetic retinopathy. EMBO J 21:4307–4316PubMedCrossRef
38.
Tarallo S, Beltramo E, Berrone E, Porta M (2012) Human pericyte–endothelial cell interactions in co-culture models mimicking the diabetic retinal microvascular environment. Acta Diabetol (epub ahead of print)
39.
Gao BB, Clermont A, Rook S et al (2007) Extracellular carbonic anhydrase mediates haemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13:181–188PubMedCrossRef
40.
El-Mesallamy HO, Hamdy NM, Sallam AA (2012) Effect of obesity and glycemic control on serum lipocalins and insulin-like growth factor axis in type 2 diabetic patients. Acta Diabetol (epub ahead of print)
41.
Suraci C, Mulas F, Rossi MC et al (2012) Management of newly diagnosed patients with type 2 diabetes: what are the attitudes of physicians? A SUBITO!AMD survey on the early diabetes treatment in Italy. Acta Diabetol (epub ahead of print)
42.
Sartore G, Chilelli NC, Burlina S et al (2012) The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Acta Diabetol (epub ahead of print)
43.
Mannucci E, Monami M, Lamanna C, Adalsteinsson JE (2012) Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetol 49:307–314PubMedCrossRef
44.
Miller ME, Bonds DE, Gerstein HC, for the ACCORD Investigators et al (2010) The effects of baseline characteristics, glycaemia treatment approach, and glycated hemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 340:b5444. doi:10.​1136/​bmj.​b5444 PubMedCrossRef
45.
Klein R, Klein BE, Moss SE et al (1989) Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 149:2427–2432PubMedCrossRef
46.
UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of microvascular complications in type 2 diabetes. UKPDS 38. BMJ 317:703–713CrossRef
47.
Ruggenenti P, Iliev I, Filipponi M et al (2010) Effect on trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the BENEDICT trial. J Ophthalmol 2010:106384PubMed
48.
Chaturvedi N, Sjolie AK, Stephenson JM et al (1998) Effects of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351:28–31
49.
Chatuvedi N, Porta M, Klein R et al (2008) Effects of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372:1394–1402CrossRef
50.
Gattu AK, Birkenfeld AL, Jornayvaz F et al (2012) Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patients. Acta Diabetol (epub ahead of print)
51.
Sambataro M, Perseghin G, Lattuada G et al (2012) Lipid accumulation in overweight type 2 diabetic subjects: relationships with insulin sensitivity and adipokines. Acta Diabetol (epub ahead of print)
52.
Keech AC, Mitchell P, Summanen PA et al (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370:1687–1697PubMedCrossRef
53.
Biscetti F, Gaetani E, Flex A et al (2008) Selective activation of peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial frowth factor-dependant mechanism. Diabetes 57:1394–1404PubMedCrossRef
54.
da Vico L, Monami M, Biffi B et al (2012) Targeting educational therapy for type 2 diabetes: identification of predictors of therapeutic success. Acta Diabetol (epub ahead of print)
55.
Bresnik GH (1986) Diabetic macular edema: a review. Ophthalmology 93:989–997
56.
Diabetes Control and Complications Trial/Epidemiology of Diabetes Inteventions and Complications (DCCT/EDIC) Research Group (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration. Arch Int Med 169:1307–1316CrossRef
57.
Zhang X, Saaddine JB, Chou CF et al (2010) Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 304:649–656PubMedCrossRef
58.
Klein R, Lee KE, Gangnon RE et al (2010) The 25-year incidence of visual impairment in type 1 diabets mellitus. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 117:63–70PubMedCrossRef
59.
Grauslund J, Green A, Sjolie AK et al (2009) Blindness in a 25-year follow-up of a population-based cohort of Danish type 1 diabetic patients. Ophthalmology 116:2170–2174PubMedCrossRef
60.
Chen E, Looman M, Laouri M et al (2010) Burden of ilness of diabetic macular edema: literature review. Curr Med Res Opin 26:1587–1597PubMedCrossRef
61.
Javitt JC, Aiello LP (1996) Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 124:164–169PubMed
62.
Aiello LP, Gardner TW, King GL et al (1998) Diabetic retinopathy. Diabetes Care 21:78–94
63.
Bandello F, Battaglia Parodi M, Tremolada G et al (2010) Steroids as part of combination treatment: the future for the management of macular edema? Ophthalmologica 224(Suppl 1):41–45PubMedCrossRef
64.
Early Treatment Diabetic Retinopathy Study Research Group (1987) Photocoagulation for diabetic macular edema: ETDRS report number 4. Int Ophthalmol Clin 27:265–272CrossRef
65.
Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103:1796–1806CrossRef
66.
Schatz H, Madeira D, McDonald HR, Johnson RN (1991) Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 109:1549–5151PubMedCrossRef
67.
Jain A, Collen J, Kaines A et al (2010) Short-duration focal pattern grid macular photocoagulation for diabetic macular edema: four-month outcomes. Retina 30:1622–1626PubMedCrossRef
68.
Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology 94:761–774
69.
Brancato R, Menchini U, Scialdone A, Bandello F (1988) Focal versus scattered argon-green in diffuse macular edema: a prospective randomized trial. In: Gitter KA, Schatz H, Yannuzzi LA, Mc Donald HR (eds) Laser photocoagulation of retinal disease. San Francisco Pacific Medical Press, pp 69–73
70.
Writing Committee for the Diabetic Retinopathy Clinical Research Network (2007) Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 125:469–480CrossRef
71.
Bandello F, Polito A, Borrello MD et al (2005) ‘Light’ versus ‘classic’ laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol 89:864–870PubMedCrossRef
72.
Desmettre TJ, Mordon SR, Buzawa DM et al (2006) Micropulse and continuous wave diode retinal photocoagulation: visible and subvisible lesion parameters. Br J Ophthalmol 90:709–712PubMedCrossRef
73.
Vujosevic S, Bottega E, Casciano M et al (2010) Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 30:908–916PubMedCrossRef
74.
Kumar V, Ghosh B, Mehta DK, Goel N (2010) Functional outcome of subthreshold versus threshold diode laser photocoagulation in diabetic macular oedema. Eye 24:1459–1465PubMedCrossRef
75.
Figueira J, Khan J, Nunes S et al (2008) Prospective randomized controlled trial comparing subthreshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 93:1341–1344PubMedCrossRef
76.
Lavinsky D, Cardillo JA, Melo LAS et al (2011) Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 52:4314–4323PubMedCrossRef
77.
Cardillo JA (2012) 577 nm MicroPulse laser therapy: addressing the immediate need of our patients with DME. In: Retina Today, vol 7, pp 11–14
78.
Paulus YM, Jain A, Nomoto H et al (2011) Selective retinal therapy with microsecond exposures using a continuous line scanning laser. Retina 31:380–388PubMedCrossRef
79.
Blumenkranz MS, Yellachich D, Andersen DE et al (2006) Semiautomated patterned scanning laser for retinal photocoagulation. Retina 26:370–376PubMedCrossRef
80.
Paulus YM, Jain A, Gariano RF et al (2008) Healing of retinal photocoagulation lesions. Invest Ophthalmol Vis Sci 49:5540–5545PubMedCrossRef
81.
Muqit MM, Marcellino GR, Gray JC et al (2010) Pain responses of Pascal 20 ms multi-spot and 100 ms single-spot panretinal photocoagulation: Manchester Pascal Study, MAPASS report 2. Br J Ophthalmol 94:1493–1498PubMedCrossRef
82.
Nagpal M, Marlecha S, Nagpal K (2010) Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser. Retina 30:452–458PubMedCrossRef
83.
Sheth S, Lanzetta P, Veritti D et al (2011) Experience with the Pascal® photocoagulator: an analysis of over 1,200 laser procedures with regard to parameter refinement. Indian J Ophthalmol 59:87–91PubMedCrossRef
84.
Inagaki K, Ohkoshi K, Ohde S (2012) Spectral-domain optical coherence tomography imaging of retinal changes after conventional multicolor laser, subthreshold micropulse diode laser, or pattern scanning laser therapy in Japanese with macular edema. Retina 32:1592–1600PubMedCrossRef
85.
Kozak I, Oster SF, Cortes MA et al (2011) Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. Ophthalmology 118:1119–1124PubMedCrossRef
86.
Kernt M, Cheuteu RE, Cserhati S et al (2012) Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas). Clin Ophthalmol 6:289–296PubMedCrossRef
87.
Ober MD, Kernt M, Cortes MA, Kozak I (2012) Time required for navigated macular laser photocoagulation treatment with the Navilas®. Graefes Arch Clin Exp Ophthalmol (epub ahead of print)
88.
Diabetic Retinopathy Group (1978) Photocoagulation of proliferative diabetic retinopathy study findings. Ophthalmology 85:82–105
89.
Diabetic Retinopathy Study Research Group (1976) Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976:383–396
90.
Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 98:S766–S785
91.
Jain A, Blumenkranz MS, Paulus Y et al (2008) Effect of pulse duration on size and character of the lesion in retinal photocfoagulation. Arch Ophthalmol 126:78–85PubMedCrossRef
92.
Sanghvi C, Mc Lauchlan R, Delgado C et al (2008) Initial experience with the Pascal® Photocoagulator: a pilot study of 75 procedures. Br J Ophthalmol 92:1061–1064PubMedCrossRef
93.
Muqit MM, Gray JC, Marcellino GR et al (2009) Fundus autofluorescence and Fourier-domain optical coherence tomography imaging of 10 and 20 millisecond Pascal® photocoagulation treatment. Br J Ophthalmol 3:518–525CrossRef
94.
DRCR Network (2009) Observational study of the development of diabetic macula edema following panretinal (scatter) photocoagulation (PRP) given in 1 or 4 sittings. Arch Ophthalmol 127:132–140CrossRef
95.
Neubauer AS, Kernt M, Haritoglou C et al (2010) Image quality of a novel navigated retina laser (NAVILAS). Fort Lauderdale: ARVO 2010 (Abstract 1639)
96.
97.
Lee SS, Hughes PM, Robinson MR (2009) Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr Opin Ophthalmol 20:511–519PubMedCrossRef
98.
Nauck M, Roth M, Tamm M et al (1998) Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down-regulated by corticosteroids. Am J Respir Cell Mol Biol 16:398–406
99.
Tamura H, Miyamoto K, Kiryu J et al (2005) Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46:1440–1444PubMedCrossRef
100.
Haller JA, Bandello F, Belfort R Jr, OZURDEX GENEVA Study Group et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146PubMedCrossRef
101.
Antonetti DA, Barber AJ, Khin S, Penn State Retina Research Group et al (1998) Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin content in retinal endothelial cells. Diabetes 47:1953–1959PubMedCrossRef
102.
Antonetti DA, Wolpert EB, DeMaio L et al (2002) Hydrocortisone decrease retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 80:667–677PubMedCrossRef
103.
Nauck M, Karakiulakis G, Perruchoud AP et al (1998) Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341:309–315PubMedCrossRef
104.
Diabetic Retinopathy Clinical Research Network (2009) Three-year follow-up of a randomized clinical trial comparing focal/grid laser photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127:245–251CrossRef
105.
Diabetic Retinopathy Clinical Research Network (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:1064–1077.e35CrossRef
106.
Diabetic Retinopathy Clinical Research Network (2011) Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118:609–614CrossRef
107.
Campochiaro PA, Brown DM, Pearson A, Ciulla T, FAME Study Group et al (2011) Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 118:626–635PubMedCrossRef
108.
Haller JA, Kuppermann BD, Blumenkranz MS et al (2010) Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 128:289–296PubMedCrossRef
109.
Blankenship GW (1991) Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications. Graefes Arch Clin Exp Ophthalmol 229:62–65PubMedCrossRef
110.
Cunningham MA, Edelman JL, Kaushal S (2008) Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol 53:139–149PubMedCrossRef
111.
Grover D, Li TJ, Chong CC (2008) Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev (1):CD005656
112.
Kuo CH, Gillies MC (2009) Role of steroids in the treatment of diabetic macular edema. Int Ophthalmol Clin 49:121–134PubMedCrossRef
113.
114.
Silva PS, Sun JK, Aiello LP (2009) Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin Ophthalmol 24:93–99PubMedCrossRef
115.
Yilmaz T, Weaver CD, Gallagher MJ et al (2009) Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 116:902–911PubMedCrossRef
116.
Audren F, Erginay A, Haouchine B et al (2006) Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 84:624–630PubMedCrossRef
117.
Massin P, Audren F, Haouchine B et al (2004) Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111:218–224PubMedCrossRef
118.
Avitabile T, Longo A, Reibaldi A (2005) Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 140:695–702PubMedCrossRef
119.
Jonas JB, Kampperter BA, Harder B et al (2006) Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 22:200–207PubMedCrossRef
120.
Gillies MC, Sutter FK, Simpson JM et al (2006) Intravitreal triamcinolone for refractory diabetic macular edema two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533–1538PubMedCrossRef
121.
Sutter FK, Simpson JM, Gillies MC (2004) Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo controlled clinical trial. Ophthalmology 111:2044–2049PubMedCrossRef
122.
Bressler NM, Edwards AR, Beck RW et al (2009) Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 127:1566–1571PubMedCrossRef
123.
Gillies MC, Simpson JM, Gaston C et al (2009) Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 116:2182–2187PubMedCrossRef
124.
Diabetic Retinopathy Clinical Research Network (2011) Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 31:1009–1027CrossRef
125.
Gillies MC, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, Wong TY (2011) Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology 118:866–872PubMedCrossRef
126.
Mirshahi A, Shenazandi H, Lashay A et al (2010) Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Retina 30:254–259PubMedCrossRef
127.
Funatsu H, Noma H, Mimura T et al (2009) Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116:73–79PubMedCrossRef
128.
Haller JA, Dugel P, Weinberg DV et al (2009) Evaluation of safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 29:46–51PubMedCrossRef
129.
Kuppermann BD, Blumenkranz MS, Haller JA et al (2007) Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125:309–317PubMedCrossRef
130.
Chin HS, Park TS, Moon YS, Oh JH (2005) Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and non-vitrectomized eyes. Retina 25:556–560PubMedCrossRef
131.
Boyer DS, Faber D, Gupta S, for the Ozurdex Champlain Study Group et al (2011) Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 31:915–923PubMedCrossRef
132.
133.
134.
Jaffe GJ, Martin D, Callanan D, Fluocinolone Acetonide Uveitis Study Group et al (2006) Fluocinolone acetonide implant (Retisert) for non infectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113:1020–1027PubMedCrossRef
135.
Pearson PA, Comstock TL, Ip M et al (2011) Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 118:1580–1587PubMedCrossRef
136.
Campochiaro PA, Hafiz G, Shah SM, Famous Study Group et al (2010) Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 117:1393–1399PubMedCrossRef
137.
Campochiaro PA, Brown DM, Pearson A et al (2012) Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119:2125–2132
138.
Bandello F, Cunha-Vaz J, Chong NV et al (2012) New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye 26:485–493PubMedCrossRef
139.
Massin P, Bandello F, Garweg JG et al (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399–2405PubMedCrossRef
140.
Nguyen QD, Brown DM, Marcus DM, RISE and RIDE Research Group et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801PubMedCrossRef
141.
Nguyen QD, Shah SM, Heier JS, READ-2 Study Group et al (2009) Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 116:2175–2181.e1PubMedCrossRef
142.
Nguyen QD, Shah SM, Khwaja AA, READ-2 Study Group et al (2010) Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 117:2146–2151PubMedCrossRef
143.
Mitchell P, Bandello F, Schmidt-Erfurth U, RESTORE Study Group et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615–625PubMedCrossRef
144.
Nguyen QD, Tatlipinar S, Shah SM et al (2006) Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142:961–969PubMedCrossRef
145.
146.
147.
148.
149.
150.
Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM et al (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114:1860–1867PubMedCrossRef
151.
Lam DS, Lai TY, Lee VY et al (2009) Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 29:292–299PubMedCrossRef
152.
Arevalo JF, Sanchez JG, Wu L, Pan-American Collaborative Retina Study Group et al (2009) Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 116:1488–1497PubMedCrossRef
153.
Kook D, Wolf A, Kreutzer T et al (2008) Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 28:1053–1060PubMedCrossRef
154.
Michaelides M, Kaines A, Hamilton RD et al (2010) A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117:1078–1086.e2PubMedCrossRef
155.
Rajendram R, Fraser-Bell S, Kaines A et al (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130:972–979
156.
Paccola L, Costa RA, Folgosa MS et al (2008) Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 92:76–80PubMedCrossRef
157.
Shimura M, Nakazawa T, Yasuda K et al (2008) Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145:854–861PubMedCrossRef
158.
Soheilian M, Ramezani A, Obudi A et al (2009) Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116:1142–1150PubMedCrossRef
159.
Avery RL, Pearlman J, Pieramici DJ et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695.e1-15PubMed
160.
Jorge R, Costa RA, Calucci D et al (2006) Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26:1006–1013PubMedCrossRef
161.
Moradian S, Ahmadieh H, Malihi M et al (2008) Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246:1699–1705PubMedCrossRef
162.
Huang YH, Yeh PT, Chen MS et al (2009) Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 29:1134–1140PubMedCrossRef
163.
Mirshahi A, Roohipoor R, Lashay A et al (2008) Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 18:263–269PubMed
164.
Grover S, Gupta S, Sharma R et al (2009) Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 93:273–274PubMedCrossRef
165.
Costagliola C, Cipollone U, Rinaldi M et al (2008) Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol 66:667–673PubMed
166.
Lim TH, Bae SH, Cho YJ et al (2009) Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol 23:188–192PubMedCrossRef
167.
Eid TM, Radwan A, el-Manawy W, el-Hawary I (2009) Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthalmol 44:451–456PubMedCrossRef
168.
Hasanreisoglu M, Weinberger D, Mimouni K et al (2009) Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol 19:607–612PubMed
169.
Ciftci S, Sakalar YB, Unlu K et al (2009) Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma. Eur J Ophthalmol 19:1028–1033PubMed
170.
Gragoudas ES, Adamis AP, Cunningham ET Jr, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816PubMedCrossRef
171.
Cunningham ET Jr, Adamis AP, Altaweel M, Macugen Diabetic Retinopathy Study Group et al (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747–1757PubMedCrossRef
172.
Loftus JV, Sultan MB, Pleil AM, Macugen 1013 Study Group (2011) Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Invest Ophthalmol Vis Sci 52:7498–7505PubMedCrossRef
173.
Sultan MB, Zhou D, Loftus J, Macugen 1013 Study Group et al (2011) A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 118:1107–1118PubMedCrossRef
174.
Adamis AP, Altaweel M, Bressler NM, Macugen Diabetic Retinopathy Study Group et al (2006) Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113:23–28PubMedCrossRef
175.
González VH, Giuliari GP et al (2009) Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol 93:1474–1478PubMedCrossRef
176.
Hornan D, Edmeades N, Krishnan R et al (2010) Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy. Eye 24:1315–1319PubMedCrossRef
177.
Do DV, Schmidt-Erfurth U, Gonzalez VH et al (2011) The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 118:1819–1826PubMedCrossRef
178.
Do DV, Nguyen QD, Boyer D, DA VINCI Study Group et al (2012) One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119:1658–1665PubMedCrossRef
179.
180.
Singerman LJ (2007) Intravitreal bevasiranib in exudative age-related macular degeneration or diabetic macular edema. 25th annual meeting of the American Society of Retina Specialists, Indian Wells
181.
Krishnadev N, Forooghian F, Cukras C et al (2011) Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 249:1627–1633PubMedCrossRef
182.
Dugel PU, Blumenkranz MS, Haller JA et al (2012) A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology 119:124–131PubMedCrossRef
183.
Stefansson E (2006) Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 51:364–380PubMedCrossRef
184.
Stefansson E, Hatchell DL, Fisher BL et al (1986) Panretinal photocoagulation and retinal oxygenation in normal and diabetic cats. Am J Ophthalmol 101:657–664PubMed
185.
Stefansson E, Landers MBI, Wolbarsht ML (1981) Increased retinal oxygen supply following panretinal photocoagulation and vitrectomy and lensectomy. Trans Am Acad Ophthalmol Soc 79:307–334
186.
Wakabayashi Y, Usui Y, Okunuki Y et al (2012) Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 53:6403–6410
187.
Yamamoto T, Akabane N, Takeuchi S (2001) Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 132:369–377PubMedCrossRef
188.
Ikeda T, Sato K, Katano T, Hayashi Y (2000) Improved visual acuity following pars plana vitrectomy for diabetic cystoid macular edema and detached posterior hyaloid. Retina 20:220–222PubMedCrossRef
189.
Lewis H, Abrams GW, Blumenkranz MS, Campo RV (1992) Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 99:753–759PubMed
190.
Watanabe M, Oshima Y, Emi K (2000) Optical cross-sectional observation of resolved diabetic macular edema associated with vitreomacular separation. Am J Ophthalmol 129:264–267PubMedCrossRef
191.
192.
193.
Diabetic Retinopathy Clinical Research Network Writing Committee, on behalf of the DRCR.​net (2010) Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 117:1087–1093.e3
194.
Kumagai K, Furukawa M, Ogino N et al (2009) Long-term follow-up of vitrectomy for diffuse non tractional diabetic macular edema. Retina 29:464–472PubMedCrossRef
195.
Gandorfer A, Messmer EM, Ulbig MW, Kampik A (2000) Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 20:126–133PubMedCrossRef
196.
van Wijngaarden P, Coster DJ, Williams KA (2005) Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293:1509–1513PubMedCrossRef
197.
Machemer R, Buettner H, Norton EW, Parel JM (1971) Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol 75:813–820PubMed
198.
Diabetic Retinopathy Vitrectomy Study Group (1990) Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 108:958–964CrossRef
199.
Thompson JT, de Bustros S, Michels RG, Rice TA (1987) Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophthalmol 105:497–502PubMedCrossRef
200.
Williams DF, Williams GA, Hartz A et al (1989) Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique. Ophthalmology 96:752–758PubMed
201.
Yang CM, Su PY, Yeh PT, Chen MS (2008) Combined rhegmatogenous and traction retinal detachment in proliferative diabetic retinopathy: clinical manifestations and surgical outcome. Can J Ophthalmol 43:192–198PubMedCrossRef
202.
Shen YD, Yang CM (2007) Extended silicone oil tamponade in primary vitrectomy for complex retinal detachment in proliferative diabetic retinopathy: a long-term follow-up study. Eur J Ophthalmol 17:954–960PubMed
203.
Virata SR, Kylstra JA, Singh HT (1999) Corneal epithelial defects following vitrectomy surgery using hand-held, sew-on, and noncontact viewing lenses. Retina 19:287–290PubMedCrossRef
204.
Yorston D, Wickham L, Benson S et al (2008) Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol 92:365–368PubMedCrossRef
205.
Newman DK (2010) Surgical management of the late complications of proliferative diabetic retinopathy. Eye 24:441–449PubMedCrossRef
206.
Gupta B, Wong R, Sivaprasad S, Williamson TH (2012) Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. Eye 26:576–582PubMedCrossRef
207.
Jonas JB, Söfker A, Degenring R (2003) Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 13:468–473PubMed
208.
Lee GH, Ahn JK, Park YG (2008) Intravitreal triamcinolone reduces the morphologic changes of ciliary body after pars plana vitrectomy for retinal vascular diseases. Am J Ophthalmol 145:1037–1044PubMedCrossRef
209.
Kim YT, Kang SW, Kim SJ et al (2012) Combination of vitrectomy, IVTA, and laser photocoagulation for diabetic macular edema unresponsive to prior treatments; 3-year results. Graefes Arch Clin Exp Ophthalmol 250:679–984PubMedCrossRef
210.
Yamakiri K, Sakamoto T, Noda Y et al (2008) One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 246:959–966PubMedCrossRef
211.
Rizzo S, Genovesi-Ebert F, Di Bartolo E et al (2008) Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246:837–842PubMedCrossRef
212.
West JF, Gregor ZJ (2000) Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy. Br J Ophthalmol 84:822–825PubMedCrossRef
213.
Oshima Y, Shima C, Wakabayashi T et al (2009) Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 116:927–938PubMedCrossRef
214.
Arevalo JF, Maia M, Flynn HW Jr et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216PubMedCrossRef
215.
Lopez-Lopez F, Rodriguez-Blanco M, Gomez-Ulla F et al (2009) Enzymatic vitreolysis. Curr Diabetes Rev 5:57–62PubMedCrossRef
216.
Kuppermann BD, Thomas EL, de Smet MD et al (2005) Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 140:573–584PubMedCrossRef
217.
Benz MS, Packo KH, Gonzalez V et al (2010) A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology 117:791–797PubMedCrossRef
Metadata
Title
Pathophysiology and treatment of diabetic retinopathy
Authors
Francesco Bandello
Rosangela Lattanzio
Ilaria Zucchiatti
Claudia Del Turco
Publication date
01-02-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-012-0449-3

Other articles of this Issue 1/2013

Acta Diabetologica 1/2013 Go to the issue

Original Article

A comparison on insulin regimen treatment of elderly (>70 years) and younger (<70 years) type 2 diabetic patients in actual clinical practice

Case Report

G6PD deficiency-induced hemolysis in a Chinese diabetic patient: a case report with clinical and molecular analysis

Original Article

Transglutaminase 2 transamidation activity during first-phase insulin secretion: natural substrates in INS-1E

Original Article

Adipocytokines mark insulin sensitivity in euthyroid Hashimoto’s patients

Original Article

Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes

Original Article

Factors associated with a rapid normalization of HbA1c in newly diagnosed type 2 diabetes patients seen in a specialist setting
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits